| Cheyenne Boucher, MS CCC-SLP | |
|
26 Best St, Belmont, NH 03220-4201 | |
| (603) 267-6568 | |
| Not Available |
| Full Name | Cheyenne Boucher |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 26 Best St, Belmont, New Hampshire |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326766981 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 2241 (New Hampshire) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Cheyenne Boucher, MS CCC-SLP 26 Best St, Belmont, NH 03220-4201 Ph: (603) 267-6568 | Cheyenne Boucher, MS CCC-SLP 26 Best St, Belmont, NH 03220-4201 Ph: (603) 267-6568 |
News Archive
Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the U.S. Food and Drug Administration has approved ILUVIEN for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).
Americans for Tax Reform today released an analysis showing the impact on Massachusetts of Marsha Coakley's support for the Senate healthcare bill. Coakley is on record supporting the Senate government healthcare bill, which contains eighteen separate tax increases. One of these is a new $2 billion per year (rising to $3 billion in 2017) tax on medical device manufacturers.
Local vaginal estrogen (VE) appears to have escaped the shroud of doubt cast upon hormone therapy as a result of the Women's Health Initiative Study by providing numerous medical benefits without systemic effects. That's according to a new study reported online today in Menopause, the journal of The North American Menopause Society.
Researchers have closed a randomized clinical trial comparing gefitinib (Iressa) vs. placebo following chemotherapy and radiation for patients with non-small cell lung cancer (NSCLC) that had spread only to nearby tissues or lymph nodes. Review of interim data indicated that gefitinib would not improve survival.
A study just released by Columbia University's Mailman School of Public Health found that children who were exposed to antibiotics in the second or third trimester of pregnancy had a higher risk of childhood obesity at age 7. The research also showed that for mothers who delivered their babies by a Caesarean section, whether elective or non-elective, there was a higher risk for obesity in their offspring.
› Verified 2 days ago
Todd Butler, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 26 Best St, Belmont, NH 03220 Phone: 603-267-6568 | |
Mrs. Kelly Johnston, M.S. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 26 Best St, Belmont, NH 03220 Phone: 686-032-6765 |